Track topics on Twitter Track topics that are important to you
Kiadis Pharma has raised €23.4m of funding in a private placement of 2.6 million new shares, for developing a T-cell immunotherapy product to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT).
Original Article: Kiadis raises €23.4m to develop immunotherapy for GVHDNEXT ARTICLE
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...